Thayer, Timothy E.
Lino Cardenas, Christian L. http://orcid.org/0000-0001-5491-4375
Martyn, Trejeeve
Nicholson, Christopher J.
Traeger, Lisa
Wunderer, Florian http://orcid.org/0000-0003-1559-0800
Slocum, Charles
Sigurslid, Haakon
Shakartzi, Hannah R.
O’Rourke, Caitlin
Shelton, Georgia
Buswell, Mary D.
Barnes, Hanna
Neitzel, Leif R.
Ledsky, Clara D.
Li, Jason Pingcheng
Burke, Megan F.
Farber-Eger, Eric
Perrien, Daniel S.
Kumar, Ravindra
Corey, Kathleen E.
Wells, Quinn S.
Bloch, Kenneth D.
Hong, Charles C. http://orcid.org/0000-0002-0424-8252
Bloch, Donald B.
Malhotra, Rajeev http://orcid.org/0000-0003-0120-4630
Funding for this research was provided by:
American Heart Association (11FTF7290032)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL142809, K08HL111210)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
Wild Family Foundation, Hassenfeld Scholar Award
Article History
Received: 13 March 2019
Accepted: 5 May 2020
First Online: 19 June 2020
Competing interests
: Massachusetts General Hospital has applied for patents related to small molecule inhibitors of BMP type I receptors and the application of ALK3-Fc to treat atherosclerosis and vascular calcification, and R.M., C.C.H., and the estate of K.D.B. may be entitled to royalties. C.C.H. holds additional patents on composition of matter and methods of use of small molecule BMP inhibitors, and has licensed the technology to La Jolla Pharmaceutical Co. for clinical development. R.M. receives consultant fees from Myokardia and Third Pole, is a co-founder of Patch, and is an article author for Up to Date. All other authors have no competing interests.